U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06977061) titled 'Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression' on April 30.
Brief Summary: Efficacy and safety of fruquintinib in combination with sintilizumab and SBRT in the treatment of oligonadenocarcinoma progression in the stomach or gastroesophageal junction
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Gastric Neoplasm
Intervention:
DRUG: Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy
no other ...